COVID-Inflicted Coagulopathy : Expert Consensus on Management with Novel Oral Anticoagulants in India
© Journal of the Association of Physicians of India 2011..
Coronavirus disease 2019 (COVID-19) is a highly hypercoagulable viral infection complicated as COVID-inflicted coagulopathy (CIC), that is associated with increased risk of morbidity and mortality. International guidelines recommend low molecular weight heparin (LMWH) to treat CIC in both in-hospital and in-home settings. However, in India, using subcutaneous LMWH may not be a feasible option for a vast majority of patients under home management. Additionally, while some evidence advocates the use of novel oral anticoagulants (NOACs), in hospitalized settings, most guidelines find no role of NOACs in hospital settings. On the other hand, the resource crunch faced in recent COVID-19 pandemic in India forced physicians to treat many patients in home settings. These patients had been usually prescribed NOACs for ease of administration and adherence. Therefore, there is a need to form a consensus on the use of NOACs to manage CIC in India.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
The Journal of the Association of Physicians of India - 69(2022), 12 vom: 21. Dez., Seite 11-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chopra, H K [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 24.01.2022 Date Revised 24.01.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM335922430 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335922430 | ||
| 003 | DE-627 | ||
| 005 | 20231225230946.0 | ||
| 007 | tu | ||
| 008 | 231225s2022 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1119.xml |
| 035 | |a (DE-627)NLM335922430 | ||
| 035 | |a (NLM)35057603 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chopra, H K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-Inflicted Coagulopathy |b Expert Consensus on Management with Novel Oral Anticoagulants in India |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2022 | ||
| 500 | |a Date Revised 24.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Journal of the Association of Physicians of India 2011. | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) is a highly hypercoagulable viral infection complicated as COVID-inflicted coagulopathy (CIC), that is associated with increased risk of morbidity and mortality. International guidelines recommend low molecular weight heparin (LMWH) to treat CIC in both in-hospital and in-home settings. However, in India, using subcutaneous LMWH may not be a feasible option for a vast majority of patients under home management. Additionally, while some evidence advocates the use of novel oral anticoagulants (NOACs), in hospitalized settings, most guidelines find no role of NOACs in hospital settings. On the other hand, the resource crunch faced in recent COVID-19 pandemic in India forced physicians to treat many patients in home settings. These patients had been usually prescribed NOACs for ease of administration and adherence. Therefore, there is a need to form a consensus on the use of NOACs to manage CIC in India | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 700 | 1 | |a Nair, Tiny |e verfasserin |4 aut | |
| 700 | 1 | |a Ponde, C K |e verfasserin |4 aut | |
| 700 | 1 | |a Kaul, Subhash |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Yatin |e verfasserin |4 aut | |
| 700 | 1 | |a Vora, Agam |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhopadhyay, Pinaki |e verfasserin |4 aut | |
| 700 | 1 | |a Jayagopal, P B |e verfasserin |4 aut | |
| 700 | 1 | |a Behera, Mrutyunjay |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Deshpande, Mahesh |e verfasserin |4 aut | |
| 700 | 1 | |a Anantharaman, R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of the Association of Physicians of India |d 1961 |g 69(2022), 12 vom: 21. Dez., Seite 11-12 |w (DE-627)NLM000004707 |x 0004-5772 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2022 |g number:12 |g day:21 |g month:12 |g pages:11-12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2022 |e 12 |b 21 |c 12 |h 11-12 | ||